The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer
Abstract
Chemoresistance is one of the causes of adverse effects in gastric cancer, including a poor response to cisplatin (DDP). Exosomes loaded with microRNA (miRNA), mRNA, and other non-coding RNAs could regulate drug resistance. Exo-anti-214 was extracted and verified. A Cell Counting Kit-8 (CCK-8) cell viability assay, flow cytometry, and transwell and immunofluorescence assays were performed to determine whether exo-anti-214 could sensitize cells to DDP in vitro. A combination of intravenously injected exo-anti-214 and intraperitoneal DDP was utilized in vivo. Additionally, potential targets of miR-214 were screened by mass spectrometry (MS) and confirmed via western blotting (WB). The levels of miR-214 in the human immortalized gastric epithelial cell line ges-1 and the human gastric adenocarcinoma cell lines SGC7901 and SGC7901/DDP gradually increased. Exo-anti-214 could fuse with cells and regulate potential targets, reducing cell viability, suppressing migration, and promoting apoptosis in vitro. Caudally injected exo-anti-214 was applied to reverse chemoresistance and repress tumor growth in vivo due to the downregulation of miR-214 and overexpression of possible target proteins in tumors. Exo-anti-214 could reverse the resistance to DDP in gastric cancer, which might serve as a potential alternative for the treatment of cisplatin-refractory gastric cancer in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Exosomes act as nanoparticles to transport anti-miR-214, effectively reversing GC’s resistance to cisplatin.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [102]
Citations
Cites
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614
Self-citationToxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Research works printed but not linked: 37
- Digklia, 2016, Advanced gastric cancer: current treatment landscape and future perspectives, World J. Gastroenterol., 22, 2403, 10.3748/wjg.v22.i8.2403 · DOI
- Cho, 2014, VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance, Int. J. Cancer, 135, 1553, 10.1002/ijc.28801 · DOI
- Marin, 2016, Mechanisms of resistance to chemotherapy in gastric cancer, Anticancer. Agents Med. Chem., 16, 318, 10.2174/1871520615666150803125121 · DOI
- Fojo, 2007, Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs, Drug Resist. Updat., 10, 59, 10.1016/j.drup.2007.02.002 · DOI
- Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
- Penna, 2015, miR-214 as a key hub that controls cancer networks: small player, multiple functions, J. Invest. Dermatol., 135, 960, 10.1038/jid.2014.479 · DOI
- Lee, 2009, Twist-1 regulates the miR-199a/214 cluster during development, Nucleic Acids Res., 37, 123, 10.1093/nar/gkn920 · DOI
- Wang, 2014, Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer, Br. J. Cancer, 110, 1199, 10.1038/bjc.2014.14 · DOI
- Zhang, 2010, Dysregulation of miR-15a and miR-214 in human pancreatic cancer, J. Hematol. Oncol., 3, 46, 10.1186/1756-8722-3-46 · DOI
- Yanaihara, 2006, Unique microRNA molecular profiles in lung cancer diagnosis and prognosis, Cancer Cell, 9, 189, 10.1016/j.ccr.2006.01.025 · DOI · Paper page
- Wang, 2014, Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma, Pediatr. Blood Cancer, 61, 206, 10.1002/pbc.24763 · DOI
- Yang, 2008, MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN, Cancer Res., 68, 425, 10.1158/0008-5472.CAN-07-2488 · DOI
- Wang, 2012, MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines, Asian Pac. J. Cancer Prev., 13, 255, 10.7314/APJCP.2012.13.1.255 · DOI
- Zheng, 2017, Prognostic role of microRNAs in human gastrointestinal cancer: a systematic review and meta-analysis, Oncotarget, 8, 46611, 10.18632/oncotarget.16679 · DOI
- Liu, 2017, Prognostic value of microRNA signature in patients with gastric cancers, Sci. Rep., 7, 42806, 10.1038/srep42806 · DOI
- Ueda, 2010, Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis, Lancet Oncol., 11, 136, 10.1016/S1470-2045(09)70343-2 · DOI
- Yang, 2013, MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN, Cancer Cell Int., 13, 68, 10.1186/1475-2867-13-68 · DOI
- Xin, 2016, MicroRNA-214 promotes peritoneal metastasis through regulating PTEN negatively in gastric cancer, Clin. Res. Hepatol. Gastroenterol., 40, 748, 10.1016/j.clinre.2016.05.006 · DOI
- Zhang, 2015, Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis, Am. J. Cancer Res., 5, 821
- Zhang, 2016, The effect of antisense inhibitor of miRNA 106b ∼25 on the proliferation, invasion, migration, and apoptosis of gastric cancer cell, Tumour Biol., 37, 10507, 10.1007/s13277-016-4937-x · DOI
- Harris, 2001, Pegylation: a novel process for modifying pharmacokinetics, Clin. Pharmacokinet., 40, 539, 10.2165/00003088-200140070-00005 · DOI
- Nakanishi, 2014, Bioactive nanocarbon assemblies: nanoarchitectonics and applications, Nano Today, 9, 378, 10.1016/j.nantod.2014.05.002 · DOI
- Yang, 2015, Current advances in lanthanide ion (Ln(3+))-based upconversion nanomaterials for drug delivery, Chem. Soc. Rev., 44, 1416, 10.1039/C4CS00155A · DOI
- Ingato, 2016, Good things come in small packages: overcoming challenges to harness extracellular vesicles for therapeutic delivery, J. Control. Release, 241, 174, 10.1016/j.jconrel.2016.09.016 · DOI
- Batrakova, 2015, Using exosomes, naturally-equipped nanocarriers, for drug delivery, J. Control. Release, 219, 396, 10.1016/j.jconrel.2015.07.030 · DOI · Paper page
- Valadi, 2007, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol., 9, 654, 10.1038/ncb1596 · DOI · Paper page
- EL Andaloussi, 2013, Extracellular vesicles: biology and emerging therapeutic opportunities, Nat. Rev. Drug Discov., 12, 347, 10.1038/nrd3978 · DOI · Paper page
- Vlassov, 2012, Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials, Biochim. Biophys. Acta, 1820, 940, 10.1016/j.bbagen.2012.03.017 · DOI
- Ohno, 2013, Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells, Mol. Ther., 21, 185, 10.1038/mt.2012.180 · DOI · Paper page
- Zhang, 2016, Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma, Cancer Lett., 375, 331, 10.1016/j.canlet.2016.03.026 · DOI
- Wang, 2013, microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line, Mol. Med. Rep., 7, 1506, 10.3892/mmr.2013.1384 · DOI
- Shang, 2014, miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1, Oncogene, 33, 3267, 10.1038/onc.2013.297 · DOI
- Thomas, 2003, Progress and problems with the use of viral vectors for gene therapy, Nat. Rev. Genet., 4, 346, 10.1038/nrg1066 · DOI · Paper page
- Lou, 2015, Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma, J. Hematol. Oncol., 8, 122, 10.1186/s13045-015-0220-7 · DOI · Paper page
- Stiff, 2004, ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation, Cancer Res., 64, 2390, 10.1158/0008-5472.CAN-03-3207 · DOI
- Rothkamm, 2015, DNA damage foci: meaning and significance, Environ. Mol. Mutagen., 56, 491, 10.1002/em.21944 · DOI
- Lobb, 2015, Optimized exosome isolation protocol for cell culture supernatant and human plasma, J. Extracell. Vesicles, 4, 27031, 10.3402/jev.v4.27031 · DOI
Cited by
Sorted by citations
Engineered Extracellular Vesicles for Cancer Therapy
Zhang, X., Zhang, H., Gu, J., Zhang, J., Shi, H., Qian, H., Wang, D., Xu, W., Pan, J., & Santos, H. A. (2021) · Advanced Materials · doi:10.1002/adma.202005709 · Cited by 428
Self-citationRecent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer
Lin, X.-M., Li, S., Zhou, C., Li, R.-Z., Wang, H., Luo, W., Huang, Y.-S., Chen, L.-K., Cai, J.-L., Wang, T.-X., et al. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105610 · Cited by 43
Metadata
- Authors
- Wang, X., Zhang, H., Bai, M., Ning, T., Ge, S., Deng, T., Liu, R., Zhang, L., Ying, G., & Ba, Y.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 26
- Issue
- 3
- Pages
- 774-783
- ISSN
- 1525-0016
- Cited by
- 192
- References
- 2
- Language
- en
- Licence
- Funders
- National Natural Science Foundation of China (81602158, 81602156, 81702437, 81702431, 81772629, 81772843)
- Tianjin Health and Family Planning Commission Foundation of Science and Technology (15KG142)
- Nature Science Foundation of Tianjin City (16PTSYJC00170)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review